Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Clinical Trial

Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial

Author(s): Yiguo Tang, Yulu Wu, Xiaojing Li, QinJian Hao, Wei Deng, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Guangya Zhang, Chuanwei Li, Xiangdong Du, Xun Hu, Tao Li* and Qiang Wang*

Volume 21, Issue 2, 2023

Published on: 30 November, 2022

Page: [424 - 436] Pages: 13

DOI: 10.2174/1570159X21666221118164612

Price: $65

Abstract

Background: Since the early clinical efficacy of antipsychotics has not yet been well perceived, this study sought to decide whether the efficacy of antipsychotics at week 2 can predict subsequent responses at week 6 and identify how such predictive capacities vary among different antipsychotics and psychotic symptoms.

Methods: A total of 3010 patients with schizophrenia enrolled in a randomized controlled trial (RCT) and received a 6-week treatment with one antipsychotic drug randomly chosen from five atypical antipsychotics (risperidone 2-6 mg/d, olanzapine 5-20 mg/d, quetiapine 400-750 mg/d, aripiprazole 10-30 mg/d, and ziprasidone 80-160 mg/d) and two typical antipsychotics (perphenazine 20-60 mg/d and haloperidol 6-20 mg/d). Early efficacy was defined as the reduction rate using the Positive and Negative Syndrome Scale (PANSS) total score at week 2. With cut-offs at 50% reduction, logistic regression, receiver operating characteristic (ROC) and random forests were adopted.

Results: The reduction rate of PANSS total score and improvement of psychotic symptoms at week 2 enabled subsequent responses to 7 antipsychotics to be predicted, in which improvements in delusions, lack of judgment and insight, unusual thought content, and suspiciousness/ persecution were endowed with the greatest weight.

Conclusion: It is robust enough to clinically predict treatment responses to antipsychotics at week 6 using the reduction rate of PANSS total score and symptom relief at week 2. Psychiatric clinicians had better determine whether to switch the treatment plan by the first 2 weeks.

Keywords: Antipsychotics, early efficacy, subsequent response, predictive capacity, RCT, schizophrenia.

« Previous
Graphical Abstract
[1]
Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 1976, 192(4238), 481-483.
[http://dx.doi.org/10.1126/science.3854] [PMID: 3854]
[2]
Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 1976, 261(5562), 717-719.
[http://dx.doi.org/10.1038/261717a0] [PMID: 945467]
[3]
Kapur, S.; Remington, G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry, 2001, 50(11), 873-883.
[http://dx.doi.org/10.1016/S0006-3223(01)01251-3] [PMID: 11743942]
[4]
Kapur, S.; Arenovich, T.; Agid, O.; Zipursky, R.; Lindborg, S.; Jones, B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry, 2005, 162(5), 939-946.
[http://dx.doi.org/10.1176/appi.ajp.162.5.939] [PMID: 15863796]
[5]
Giegling, I.; Porcelli, S.; Balzarro, B.; Andrisano, C.; Schäfer, M.; Möller, H.J.; Rujescu, D.; Serretti, A. Antipsychotic response in the first week predicts later efficacy. Neuropsychobiology, 2012, 66(2), 100-105.
[http://dx.doi.org/10.1159/000337739] [PMID: 22814310]
[6]
Agid, O.; Kapur, S.; Arenovich, T.; Zipursky, R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry, 2003, 60(12), 1228-1235.
[http://dx.doi.org/10.1001/archpsyc.60.12.1228] [PMID: 14662555]
[7]
Leucht, S.; Busch, R.; Hamann, J.; Kissling, W.; Kane, J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry, 2005, 57(12), 1543-1549.
[http://dx.doi.org/10.1016/j.biopsych.2005.02.023] [PMID: 15953491]
[8]
Schennach, R.; Riesbeck, M.; Mayr, A.; Seemüller, F.; Maier, W.; Klingberg, S.; Heuser, I.; Klosterkötter, J.; Gastpar, M.; Schmitt, A.; Sauer, H.; Schneider, F.; Jäger, M.; Wölwer, W.; Gaebel, W.; Möller, H.J.; Riedel, M. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr. Scand., 2013, 127(6), 474-481.
[http://dx.doi.org/10.1111/acps.12006] [PMID: 22957829]
[9]
Samara, M.T.; Leucht, C.; Leeflang, M.M.; Anghelescu, I.G.; Chung, Y.C.; Crespo-Facorro, B.; Elkis, H.; Hatta, K.; Giegling, I.; Kane, J.M.; Kayo, M.; Lambert, M.; Lin, C.H.; Möller, H.J.; Pelayo-Terán, J.M.; Riedel, M.; Rujescu, D.; Schimmelmann, B.G.; Serretti, A.; Correll, C.U.; Leucht, S. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am. J. Psychiatry, 2015, 172(7), 617-629.
[http://dx.doi.org/10.1176/appi.ajp.2015.14101329] [PMID: 26046338]
[10]
Kinon, B.; Chen, L.; Aschersvanum, H.; Stauffer, V.; Kollackwalker, S.; Sniadecki, J.; Kane, J. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res., 2008, 102(1-3), 230-240.
[http://dx.doi.org/10.1016/j.schres.2008.02.021] [PMID: 18423985]
[11]
Lin, C.H.; Chou, L.S.; Lin, C.H.; Hsu, C.Y.; Chen, Y.S.; Lane, H.Y. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J. Clin. Psychiatry, 2007, 68(10), 1522-1527.
[http://dx.doi.org/10.4088/JCP.v68n1008] [PMID: 17960966]
[12]
Stauffer, V.L.; Case, M.; Kinon, B.J.; Conley, R.; Ascher-Svanum, H.; Kollack-Walker, S. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res., 2010, 187, 42-48.
[http://dx.doi.org/10.1016/j.psychres.2010.11.017]
[13]
Schennach-Wolff, R.; Seemüller, F.H.; Mayr, A.; Maier, W.; Klingberg, S.; Heuser, I.; Klosterkötter, J.; Gastpar, M.; Häfner, H.; Sauer, H.; Schneider, F.; Gaebel, W.; Jäger, M.; Möller, H.J.; Riedel, M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br. J. Psychiatry, 2010, 196(6), 460-466.
[http://dx.doi.org/10.1192/bjp.bp.109.069328] [PMID: 20513856]
[14]
Leucht, S.; Zhao, J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. J. Psychopharmacol., 2014, 28(4), 387-394.
[http://dx.doi.org/10.1177/0269881113517956] [PMID: 24429222]
[15]
Leucht, S.; Shamsi, S.A.R.; Busch, R.; Kissling, W.; Kane, J.M. Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study. Schizophr. Res., 2008, 101(1-3), 312-319.
[http://dx.doi.org/10.1016/j.schres.2008.01.018] [PMID: 18308513]
[16]
Schennach-Wolff, R.; Jäger, M.; Mayr, A.; Meyer, S.; Kühn, K.U.; Klingberg, S.; Heuser, I.; Klosterkötter, J.; Gastpar, M.; Schmitt, A.; Schlösser, R.; Schneider, F.; Gaebel, W.; Seemüller, F.; Möller, H.J.; Riedel, M. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response? Eur. Neuropsychopharmacol., 2011, 21(5), 370-378.
[http://dx.doi.org/10.1016/j.euroneuro.2010.10.003] [PMID: 21255982]
[17]
Schooler, N.; Rabinowitz, J.; Davidson, M.; Emsley, R.; Harvey, P.D.; Kopala, L.; McGorry, P.D.; Van Hove, I.; Eerdekens, M.; Swyzen, W.; De Smedt, G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry, 2005, 162(5), 947-953.
[http://dx.doi.org/10.1176/appi.ajp.162.5.947] [PMID: 15863797]
[18]
Chen, Y.L.; Chen, K.P.; Chiu, C.C.; Tai, M.H.; Lung, F.W. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC Psychiatry, 2018, 18(1), 376.
[http://dx.doi.org/10.1186/s12888-018-1950-1] [PMID: 30509308]
[19]
First, M.; Spitzer, R.; Gibbon, M. Structured Clinical Interview for DSM-IV Axis I Disorders--Administration Booklet; American Psychiatric Press: Washington, D.C., 1994.
[20]
Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 1987, 13(2), 261-276.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[21]
Gardner, D.M.; Murphy, A.L.; O’Donnell, H.; Centorrino, F.; Baldessarini, R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry, 2010, 167(6), 686-693.
[http://dx.doi.org/10.1176/appi.ajp.2009.09060802] [PMID: 20360319]
[22]
Barnes, T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry, 1989, 154(5), 672-676.
[http://dx.doi.org/10.1192/bjp.154.5.672] [PMID: 2574607]
[23]
Guy, E. Rockville National Institute of Mental Health, U.S. Department of Health and Human Services, M.D. Abnormal Involuntary Movement Scale. Rockville, ECDEU Assessment Manual for Psychopharmacology: revised 1976; National Institute of Mental Health, U.S. Department of Health and Human Services: Rockville, MD, 1976.
[24]
Simpson, G.M. B, M.; B, G.H.; Angus, J.W.S.; P, F.R.C.; M, D.P. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., 1970, 45(S212), 11-19.
[http://dx.doi.org/10.1111/j.1600-0447.1970.tb02066.x] [PMID: 4917967]
[25]
Obermeier, M.; Mayr, A.; Schennach-Wolff, R.; Seemüller, F.; Möller, H.J.; Riedel, M. Should the PANSS be rescaled? Schizophr. Bull., 2010, 36(3), 455-460.
[http://dx.doi.org/10.1093/schbul/sbp124] [PMID: 19889950]
[26]
Leucht, S.; Kissling, W.; Davis, J.M. The PANSS should be rescaled. Schizophr. Bull., 2010, 36(3), 461-462.
[http://dx.doi.org/10.1093/schbul/sbq016] [PMID: 20357133]
[27]
Carbon, M.; Correll, C.U. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin. Neurosci., 2014, 16(4), 505-524.
[http://dx.doi.org/10.31887/DCNS.2014.16.4/mcarbon] [PMID: 25733955]
[28]
Leucht, S.; Kane, J.; Kissling, W.; Hamann, J.; Etschel, E.; Engel, R. What does the PANSS mean? Schizophr. Res., 2005, 79(2-3), 231-238.
[http://dx.doi.org/10.1016/j.schres.2005.04.008] [PMID: 15982856]
[29]
Mossman, D.; Somoza, E. ROC curves, test accuracy, and the description of diagnostic tests. J. Neuropsychiatry Clin. Neurosci., 1991, 3(3), 330-333.
[http://dx.doi.org/10.1176/jnp.3.3.330] [PMID: 1821250]
[30]
Chang, Y.C.; Lane, H.Y.; Yang, K.H.; Huang, C.L. Optimizing early prediction for antipsychotic response in schizophrenia. J. Clin. Psychopharmacol., 2006, 26(6), 554-559.
[http://dx.doi.org/10.1097/01.jcp.0000246211.95905.8c] [PMID: 17110810]
[31]
Lieberman, J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J. Clin. Psychiatry, 2007, 68(2), e04.
[http://dx.doi.org/10.4088/JCP.0207e04] [PMID: 17335312]
[32]
Levine, S.Z.; Leucht, S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia. Schizophr. Res., 2012, 141(2-3), 168-172.
[http://dx.doi.org/10.1016/j.schres.2012.08.030] [PMID: 22995933]
[33]
Chen, L.; Ascher-Svanum, H.; Stauffer, V.; Kinon, B.J.; Kollack-Walker, S.; Ruberg, S. Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods. Schizophr. Res., 2009, 113(1), 34-40.
[http://dx.doi.org/10.1016/j.schres.2009.06.001] [PMID: 19564097]
[34]
Lambert, M.; Schimmelmann, B.G.; Naber, D.; Eich, F.X.; Schulz, H.; Huber, C.G.; Karow, A. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry, 2009, 42(6), 277-283.
[http://dx.doi.org/10.1055/s-0029-1234105] [PMID: 19924588]
[35]
Chou, Y.H.; Chiu, N.M.; Yang, T.T.; Feng, J.; Chan, C.C.; Lee, H.K. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine. Int. Clin. Psychopharmacol., 2013, 28(5), 255-260.
[http://dx.doi.org/10.1097/YIC.0b013e328363aa33] [PMID: 23820333]
[36]
Yeh, E-C.; Huang, M-C.; Tsai, C-J.; Chen, C-T.; Chen, K-Y.; Chiu, C-C. Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release. Psychiatry Res., 2015, 230(1), 13-18.
[http://dx.doi.org/10.1016/j.psychres.2015.07.037] [PMID: 26319696]
[37]
Leucht, S.; Busch, R.; Kissling, W.; Kane, J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry, 2007, 68(3), 352-360.
[http://dx.doi.org/10.4088/JCP.v68n0301] [PMID: 17388703]
[38]
Emsley, R.; Rabinowitz, J.; Medori, R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry, 2006, 163(4), 743-745.
[http://dx.doi.org/10.1176/ajp.2006.163.4.743] [PMID: 16585455]
[39]
Derks, E.M.; Fleischhacker, W.W.; Boter, H.; Peuskens, J.; Kahn, R.S.; Group, E.S. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J. Clin. Psychopharmacol., 2010, 30(2), 176-180.
[http://dx.doi.org/10.1097/JCP.0b013e3181d2193c] [PMID: 20520291]
[40]
Meltzer, H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med., 2013, 64(1), 393-406.
[http://dx.doi.org/10.1146/annurev-med-050911-161504] [PMID: 23020880]
[41]
Weinstein, MC Clinical Decision Analysis; WB Saunders: Philadelphia, 1980.
[42]
Dai, M.; Wu, Y.; Tang, Y.; Yue, W.; Yan, H.; Zhang, Y.; Tan, L.; Deng, W.; Chen, Q.; Yang, G.; Lu, T.; Wang, L.; Yang, F.; Zhang, F.; Yang, J.; Li, K.; Lv, L.; Tan, Q.; Zhang, H.; Ma, X.; Li, L.; Wang, C.; Ma, X.; Zhang, D.; Yu, H.; Zhao, L.; Ren, H.; Wang, Y.; Hu, X.; Zhang, G.; Du, X.; Wang, Q.; Li, T. Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial. BJPsych Open, 2020, 6(6), e126.
[http://dx.doi.org/10.1192/bjo.2020.105] [PMID: 33090091]
[43]
Ortiz, B.B.; Higuchi, C.H.; Noto, C.; Joyce, D.W.; Correll, C.U.; Bressan, R.A.; Gadelha, A. A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. Schizophr. Res., 2020, 218, 195-200.
[http://dx.doi.org/10.1016/j.schres.2020.01.002] [PMID: 31956005]
[44]
Kinon, B.J.; Chen, L.; Ascher-Svanum, H.; Stauffer, V.L.; Kollack-Walker, S.; Zhou, W.; Kapur, S.; Kane, J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology, 2010, 35(2), 581-590.
[http://dx.doi.org/10.1038/npp.2009.164] [PMID: 19890258]
[45]
Stentebjerg-Olesen, M.; Ganocy, S.J.; Findling, R.L.; Chang, K.; DelBello, M.P.; Kane, J.M.; Tohen, M.; Jeppesen, P.; Correll, C.U. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur. Child Adolesc. Psychiatry, 2015, 24(12), 1485-1496.
[http://dx.doi.org/10.1007/s00787-015-0725-1] [PMID: 26032132]
[46]
Leucht, S.; Davis, J.M.; Engel, R.R.; Kane, J.M.; Wagenpfeil, S. Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology, 2007, 32(9), 1903-1910.
[http://dx.doi.org/10.1038/sj.npp.1301325] [PMID: 17287825]
[47]
Leucht, S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psychiatry, 2014, 75(Suppl. 1), 8-14.
[http://dx.doi.org/10.4088/JCP.13049su1c.02] [PMID: 24581453]
[48]
Leucht, S.; Rothe, P.; Davis, J.M.; Engel, R.R. Equipercentile linking of the BPRS and the PANSS. Eur. Neuropsychopharmacol., 2013, 23(8), 956-959.
[http://dx.doi.org/10.1016/j.euroneuro.2012.11.004] [PMID: 23433639]
[49]
Leucht, S.; Engel, R.R.; Davis, J.M.; Kissling, W.; Meyer zur Capellen, K.; Schmauß, M.; Messer, T. Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. Eur. Neuropsychopharmacol., 2012, 22(7), 501-505.
[http://dx.doi.org/10.1016/j.euroneuro.2011.11.007] [PMID: 22386773]
[50]
Zhang, J.P.; Malhotra, A.K. Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin. Drug Metab. Toxicol., 2012, 9, 183-191.
[http://dx.doi.org/10.1517/17425255.2013.736964]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy